直接口服抗凝药安全性的WHO不良反应数据库分析
DOAC相比华法林胃肠道出血ROR为1.6(1.47-1.75),脑出血无比例失衡(ROR 0.31,0.28-0.34)。
要点
- DOAC相比华法林胃肠道出血报告比例更高,ROR为1.6(95%CI 1.47-1.75)。
- DOAC相比华法林脑出血报告比例更低,ROR为0.31(95%CI 0.28-0.34)。
- 三种新型口服抗凝药在ADR发生率和类型上存在差异。
核心结论
- 与华法林相比,DOACs治疗患者颅内出血风险降低但胃肠道出血风险增加。
- 三种新型口服抗凝药在ADR发生率和类型上存在差异。
研究设计与样本
- 纳入非瓣膜性房颤患者中DOAC或华法林作为可疑/相互作用药物的ADR报告。
主要发现
- 共识别204个ADR的ROR>1(P≤0.05),重点分析其中105个反应。
- DOACs相比华法林胃肠道出血ROR为1.6(95%CI 1.47-1.75)。
- DOACs相比华法林脑出血无比例失衡,ROR为0.31(95%CI 0.28-0.34)。
- 识别出若干既往未与DOACs关联的潜在信号。
临床怎么用
- 临床使用DOACs时应关注胃肠道出血风险,尤其在高危患者中。
- DOACs颅内出血风险低于华法林,但需个体化评估。
- 不同DOACs的ADR类型和发生率存在差异,选择时需考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Direct oral anticoagulants (DOACs) have shown noninferiority to warfarin for stroke prevention in nonvalvular atrial fibrillation (AF) and a more promising safety profile. Unanswered safety aspects remain to be addressed and available evidence on the risk associated with these drugs are conflicting. In order to contribute to the debate on their safety profile, we conducted a comparative analysis of the reports of suspected adverse drug reactions (ADRs) associated with DOACs in VigiBase. METHODS: Study based on reports of suspected ADRs held in VigiBase as at December 2014, in which a DOAC or warfarin were administered in patients with nonvalvular AF and listed as suspected/interacting drugs. Medical Dictionary for Regulatory Activities was used to classify ADRs. Reporting odds ratio (ROR) with 95% confidence interval were calculated. Results with P ≤ 0.05 were statistically significant. RESULTS: We retrieved 32 972 reports. We identified 204 ADRs with a ROR >1 (P ≤ 0.05) and we focused on 105 reactions. Positive ROR emerged for DOACs and gastrointestinal haemorrhage compared with warfarin [(1.6 (1.47-1.75)], but no disproportionality with cerebral haemorrhage was found [0.31 (0.28-0.34)]. We identified other potential signals that have not been associated with DOACs previously. CONCLUSIONS: As well as premarketing authorization clinical trial studies, we found a reduced risk of intracranial haemorrhage, but an increased risk of gastrointestinal haemorrhage in patients treated with DOACs compared to warfarin. We provide new data and we highlight several differences between the three novel oral anticoagulants, in the rate and type of ADRs occurred.
引用
- Monaco L, Biagi C, Conti V, et al. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol. 2017. PMID: 28071818. doi:10.1111/bcp.13234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。